Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Amphenol Corp. Cl A Stock Slides 6.4%, Underperforms Market

Amphenol Corp. Cl A Stock Slides 6.4%, Underperforms Market

Dow JonesDow Jones2026/09/14 20:35

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Amphenol Corp. Cl A slipped 6.4% to $78.55 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.5% to 7,619.98 and Dow Jones Industrial Average falling 0.3% to 52,421.20.

Amphenol Corp. Cl A closed 12.0% short of its 52-week high of $89.26, which the company reached on June 30th.

The stock demonstrated a mixed performance when compared to some of its peers, as Eaton Corp. PLC fell 7.6% to $393.16, TE Connectivity PLC fell 4.1% to $203.37, and Enphase Energy Inc. rose 0.85% to $36.66.

Trading volume totaled 12.1 million, compared to the 50-day average of 12.5 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

September 14, 2026 16:35 ET (20:35 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma